Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients

NCT ID: NCT04793399

Last Updated: 2024-03-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-24
• Study Completion Date: 2021-09-24

Brief Summary

The combination of bosutinib plus atezolizumab in first line treatment in newly diagnosis chronic-phase Chronic Myeloid Leukemia (CML) patients could potentially increase molecular responses and therefore treatment discontinuation probabilities in these patients. We propose an Open-Label Phase Ib/II Study of Bosutinib in Combination with Atezolizumab for the Treatment of New Diagnosis Chronic Phase-Chronic Myeloid Leukemia Patients.

Detailed Description

The combination of bosutinib and atezolizumab in first line treatment in newly diagnosis chronic-phase Chronic Myeloid Leukemia (CML) patients could potentially increase molecular responses and consequently treatment discontinuation probabilities in these patients. We would like to propose an Open-Label Phase Ib/II Study of Bosutinib in Combination with Atezolizumab for the Treatment of New Diagnosis Chronic Phase-Chronic Myeloid Leukemia Patients.

Conditions

Chronic Phase-Chronic Myeloid Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Bosutinib-Atezolizumab Combination

Drugs to be administered:

Bosutinib 400 milligram (mg)/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year

Group Type: EXPERIMENTAL

Bosutinib 400 MG Monotherapy

Intervention Type: DRUG

One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy

Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection

Intervention Type: DRUG

12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles

Interventions

Bosutinib 400 MG Monotherapy

One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy

Intervention Type: DRUG

Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection

12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles

Intervention Type: DRUG

Other Intervention Names

Bosulif; Bosulif + Tecentriq

Eligibility Criteria

Inclusion Criteria

1. Male or female patient ≥ 18 years of age.

2. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legal representative) has been informed of all pertinent aspects of the study.

3. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

4. Newly Patient with Philadelphia chromosome positive chronic phase CML and BCR-ABL1 transcript detected at diagnosis.

5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.

6. Adequate hepatic, renal and pancreatic function defined as:

1. Total bilirubin within normal range or Direct bilirubin ≤ 1.5 x ULN,

2. Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN) or ≤5 x ULN if attributable to liver involvement of leukemia,

7. Women of childbearing potential must have a negative pregnancy test documented prior enrollment. Women of childbearing potential and men must be using an adequate method of contraception.

Exclusion Criteria

1. Pregnant or lactating women,

2. Participation in another clinical trial with any investigational drug within 30 days prior to study enrollment,

3. Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with the exception of hydroxyurea,

4. Period of time since CML diagnosis longer than 6 months,

5. Hypersensitivity to the active substances or to any of the excipients of the bosutinib and/or atezolizumab formulations,

6. Major surgery or radiotherapy within 14 days of enrollment,

7. Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease,

8. Concomitant use of or need for medications known to prolong the QTc interval,

9. Concomitant use with strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin), moderate CYP3A inhibitors (erythromycin, fluconazole, diltiazem), or strong CYP3A inducers (rifampin, carbamazepine, phenytoin),

10. History of clinically significant or uncontrolled cardiac disease, including:

1. Stage II to IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA) classification system for heart failure.

2. Myocardial infarction within the previous 6 months,

3. Symptomatic cardiac arrhythmia requiring treatment,

4. Diagnosed or suspected congenital or acquired prolonged QT history or prolonged QTc. (QTcF should not exceed 500 msec),

11. Grade III or IV fluid retention,

12. Uncontrolled hypomagnesemia or uncorrected symptomatic hypokalemia, due to potential effects on the QTc interval,

13. Uncontrolled or symptomatic hypercalcemia,

14. Recent or ongoing clinically significant gastrointestinal (GI) disorder e.g. Crohn's Disease, Ulcerative Colitis or prior total or partial gastrectomy,

15. Autoimmune or infectious active disease that require treatment,

16. CML patient not in chronic phase at diagnosis,

17. Patients with known atypical transcript. An atypical transcript is defined by the presence of any transcript in the absence of the major transcripts b3a2 (e14a2) and b2a2 (e13a2) or p210 protein,

18. Patients with known resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V). It is not necessary to perform mutation tests on the patient to be included in the study if they were not previously performed,

19. Individuals with an active malignancy,

20. Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive) and/or hepatitis C.

21. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug.

22. Patients with severe renal impairment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: collaborator

Roche Farma, S.A

INDUSTRY

Sponsor Role: collaborator

Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Valentin Garcia, Dr.

Role: PRINCIPAL_INVESTIGATOR

Hospital Ramon y Cajal

Locations

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Hospital Universitario La Paz

Madrid, , Spain

Countries

Spain

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

ZEROLMC-01

Identifier Type: -

Identifier Source: org_study_id